What is Pulmonary Inflammatory Myofibroblastic Tumor?

Pulmonary Inflammatory Myofibroblastic Tumor (IMT) is an uncommon tumor that usually occurs in the lung and is characterized by abnormal cellular growth of myofibroblastic spindle cells, with an inflammatory reaction of plasma cells, lymphocytes, and eosinophils. In the past, this tumor has been regarded as an inflammatory reaction; however, with the advancement of medical science, it has been recognized as a true tumor that may invade other tissues and even metastasize in rare cases.

Pulmonary Inflammatory Myofibroblastic Tumor is usually found in children and young adults; however, it may occur in people of any age. This tumor usually starts in the lungs; however, it may also arise in other areas, such as the abdomen, pelvis, and soft tissues. Because of the uncommon and vague presentation of pulmonary inflammatory myofibroblastic tumors, it may be hard to diagnose this tumor and may be confused with other infectious and tumor conditions in the pulmonary area. Pulmonary Inflammatory Myofibroblastic Tumor can be considered a distinct medical condition with its own genetic characteristics, such as the ALK gene mutation. The treatment of patients with this condition has greatly improved due to recent advances in medical science.

A pulmonary inflammatory myofibroblastic tumor develops when myofibroblasts—cells that normally play a role in wound healing and tissue repair—begin to multiply abnormally and form a mass within the lung tissue. The tumors exhibit a distinctive property: they contain both malignant cells and a large proportion of immune cells. The combination of these factors gives the tumor the capacity to imitate both infectious diseases and inflammatory respiratory diseases. Research has demonstrated that many IMT cases involve genetic mutations that drive tumor development.

The mutations confirm that IMT behaves as a neoplasm, while it does not qualify as an ordinary inflammatory response to medical treatment. Pulmonary IMT exists under the umbrella of lung tumors, yet it exhibits distinct characteristics that differentiate it from typical lung cancers, such as both small cell and Non-Small Cell Lung Cancers.

What are the Causes & Risk Factors of Pulmonary Inflammatory Myofibroblastic Tumor?

The scientific community has not yet established the exact origin of pulmonary inflammatory myofibroblastic tumors. The researchers have identified several biological mechanisms underlying the development of this medical condition.

Mutations in Genes

The identification of ALK gene mutations in IMT research studies is considered the most significant contribution in this area. The patients suffering from IMT have genetic alterations in this gene, which result in improper cellular signaling pathways, causing cancer.

The occurrence of ALK rearrangements is particularly common in younger patients with IMT.

Previous Infections

Some cases appear to develop after respiratory infections or inflammatory conditions. Chronic inflammation creates conditions that enable abnormal tissue repair mechanisms to initiate tumor development.

Immune System Responses

The development of inflammatory tumors depends on two factors: abnormal immune reactions and prolonged inflammation.

Trauma or Tissue Injury

Injuries to lung tissue from prior incidents create conditions that lead to excessive myofibroblast proliferation during the healing phase.

The medical community recognizes multiple potential factors that may lead to a pulmonary IMT diagnosis, yet most patients have no identifiable risk factors.

Symptoms of pulmonary IMT vary widely depending on the size and location of the tumor. The discovery of tumors during imaging tests for other medical conditions allows some patients who show no symptoms to proceed with their medical examinations.

The symptoms of respiratory illnesses closely resemble those that develop during these episodes.

The common symptoms of the condition include:

• People experience a persistent cough.
• The patient experiences chest pain or discomfort.
• People develop difficulty in breathing.
• The patient experiences an increase in body temperature.
• Patients experience extreme tiredness during their daily activities.
• People experience unintentional weight loss.
• The patient experiences blood-tinged sputum (hemoptysis) with coughing.
• Children display symptoms such as recurrent respiratory infections and breathing difficulties.

The medical evaluation process should begin with diagnostic testing and imaging because patients must undergo these procedures for doctors to make a precise diagnosis of lung conditions.

How is Pulmonary Inflammatory Myofibroblastic Tumor Diagnosed?

To get a full picture of the diagnosis, doctors need to do a clinical exam, imaging tests, and lab tests to find pulmonary inflammatory myofibroblastic tumors.

Imaging Studies

Imaging plays a critical role in detecting lung tumors and assessing their physical characteristics.

The standard imaging methods consist of:

• The process begins with a chest X-ray.
• The process involves a chest CT scan to obtain internal images.
• The process uses a magnetic resonance imaging (MRI) system to produce detailed images of the body.

A CT scan produces precise images of the lungs that help medical professionals identify the tumor's size, shape, and location.

Biopsy

The diagnosis of IMT requires a biopsy procedure as its fundamental step. A small portion of the tumor gets extracted during this operation so professionals can study it through microscopic examination.

The pathologists study the tissue sample to detect spindle-shaped myofibroblasts and the presence of inflammatory cells.

Immunohistochemistry

Special laboratory tests are conducted to identify particular proteins present in tumor cells. ALK functions as a key marker that appears in most inflammatory myofibroblastic tumors as a common occurrence.

Molecular Testing

Genetic testing may reveal ALK gene rearrangements and other molecular changes, which doctors use to select targeted therapies.

How is Pulmonary Inflammatory Myofibroblastic Tumor Staged?

Inflammatory myofibroblastic tumors exhibit different staging patterns from other cancers because they do not always conform to established cancer staging techniques. Doctors assess multiple factors to establish the degree of disease progression:

• The dimensions of the tumor
• The tumor's position in the lung
• Close organs that the tumor has affected
• Metastasis, which occurs infrequently

Most pulmonary IMTs remain confined to their original location, although they can invade adjacent areas.

What are the treatment methods for Pulmonary Inflammatory Myofibroblastic Tumor?

Management of lung inflammatory myofibroblastic tumors is based on three main principles: tumor size, site, and genetics. This illness requires a multidisciplinary approach to its management.

Surgical Removal

Surgical procedures represent the main treatment option for the majority of pulmonary IMTs. The procedure aims to extract the tumor while preserving surrounding healthy tissue.

Surgical procedures may include:

• Wedge resection
• Lobectomy (removal of a lung lobe)
• Segmentectomy

Patients who undergo complete surgical removal experience excellent results that last over time.

Targeted Therapy

Targeted therapy becomes necessary when surgical tumor removal proves impossible or when the tumor has metastasized to other body regions.

ALK-positive tumor patients can use medications that stop ALK signaling pathways from functioning.

These pharmaceutical drugs specifically target cancer cells while minimizing damage to normal cells.

Radiation Therapy

When surgery is not an option or when patients still have malignant cells after surgery, doctors choose radiation therapy. High-energy radiation inhibits tumor growth while aiding in the removal of aberrant cells.

Chemotherapy

The treatment uses powerful medications to destroy rapidly dividing tumor cells. Chemotherapy remains an uncommon treatment for pulmonary IMT except when patients develop advanced or recurrent cases.

Anti-inflammatory Therapy

Due to the inflammatory nature of the condition, some people respond positively to corticosteroids. While it meets some of the patients' requirements, it violates established therapy procedures.

Reoccurrence and Follow-Up

There is evidence that pulmonary inflammatory myofibroblastic tumors recur despite complete recovery for most patients. It is important for patients to adhere to follow-up appointments.

Follow-up care may include:

• Periodic CT scans
• Physical examinations
• Lung function tests

Early detection of recurrence enables doctors to begin treatment without delay.

What is Prognosis for Pulmonary Inflammatory Myofibroblastic Tumor?

Pulmonary inflammatory myofibroblastic tumors have a good outlook for patients who achieve complete tumor excision through surgical procedures. Patients who undergo treatment generally experience long-term survival with few health issues.

The three factors that impact prognosis include:

• The entire tumor tissue must be removed.
• The tumor dimensions must exceed a specific threshold.
• Tumor behavior changes because of particular genetic mutations

IMTs with an aggressive growth pattern rarely metastasize to distant sites. Studies and assessments are being conducted to better understand the condition and its recurrences.

Advances in Research & Treatment

The management of inflammatory myofibroblastic tumors has greatly evolved in recent years through advances in molecular medicine. Various genetic mutations have been identified that lead to the formation of inflammatory myofibroblastic tumors, including ALK, ROS1, and other genetic translocations. As such, continued research into the role of these genetic changes in the condition is providing hope for more effective management of pulmonary IMT patients.

Based on the results, it is possible to develop drugs that target signaling pathways that drive cancer. Using precision medicine, medical professionals can select the right drugs based on tumor genetics.

Clinical trials are also exploring new therapeutic strategies for patients with advanced or recurrent disease.

Living with a Rare Lung Tumor

The diagnosis of pulmonary inflammatory myofibroblastic tumor poses significant challenges because this condition occurs infrequently and lacks widespread knowledge.

Counseling, rehabilitation, and education services form part of the supportive care measures that play an important role in assisting patients. To fully recover, it is important to live a healthy life.

Recommended lifestyle measures include:

• Avoiding tobacco exposure
• Following a balanced diet
• Participating in regular exercise
• Going to all medical follow-up appointments

Most patients may easily return to their regular daily activities after receiving appropriate medical treatment and care.

What is the Importance of Early Diagnosis of Pulmonary Inflammatory Myofibroblastic Tumor?

It is important to diagnose pulmonary inflammatory myofibroblastic tumors early to provide appropriate treatment. Individuals experiencing respiratory symptoms are advised to consult their doctors, as these symptoms may indicate other respiratory diseases. In addition, modern technology has enabled doctors to diagnose uncommon pulmonary tumors with increased accuracy.

Timely surgical intervention is possible with early detection, thereby decreasing the risk of complications.

Why choose Tender Palm Super Speciality Hospital for Pulmonary Inflammatory Myofibroblastic Tumor Treatment in Lucknow, India?

Tender Palm Super-Speciality Hospital offers advanced Pulmonary Inflammatory Myofibroblastic Tumor treatment in Lucknow, India, at an affordable cost. We have a team of experienced thoracic surgeons and oncology specialists who provide accurate diagnosis and both non-surgical and surgical treatment options including surgical resection, targeted therapy, and comprehensive oncological management procedures. Our Thoracic Surgery and Oncology team has decades of experience in successfully treating Pulmonary Inflammatory Myofibroblastic Tumor in Lucknow, India.

To seek an Expert consultation for Pulmonary Inflammatory Myofibroblastic Tumor Treatment in Lucknow, India:

Call us at +91-9076972161
Email at care@tenderpalm.com

Request a Call Back